MedPage TodayWhy the Now-Dominant BQ COVID Strains Are Cause for Concern

BQ.1 and BQ.1.1 together now comprise more than 50% of all COVID cases in the US. Their rapid rise – with prediction that these variants will account for more than 80% of infections by Jan. 1 – lead FDA to remove the emergency use authorization for bebtelovimab, and recommend bivalent boosters and the use of ritonavir-nirmatrelvir, remdesivir, and molnupiravir for treatment of infection.